Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial

Asieh Mansour, Mohammad Reza Mohajeri-Tehrani, Sara Karimi, Milad Sanginabadi, Hossein Poustchi, Samaneh Enayati, Saeedeh Asgarbeik, Javad Nasrollahzadeh, Azita Hekmatdoost, Asieh Mansour, Mohammad Reza Mohajeri-Tehrani, Sara Karimi, Milad Sanginabadi, Hossein Poustchi, Samaneh Enayati, Saeedeh Asgarbeik, Javad Nasrollahzadeh, Azita Hekmatdoost

Abstract

The aim of this study was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota, and metabolic disturbances in patients with NAFLD and diabetes. In this randomized, placebo-controlled, clinical trial, 26 patients with diabetes and NAFLD were randomly assigned to four groups to receive either 200 mg caffeine plus 200 mg chlorogenic acid (CFCA), or 200 mg caffeine plus 200 mg placebo (starch) (CFPL), or 200 mg chlorogenic acid plus 200 mg placebo (CAPL), or 200 mg placebo plus 200 mg placebo (PLPL) for 12 weeks. After 3 months of supplementation, patients in the intervention groups showed a significant decrease in body weight (CFCA group =-3.69 kg; CFPL group=-0.7kg; CAPL group=-0.43kg; PLPL group=0.26 kg) (p=0.004). Weight reduced significantly more in CFCA group compared to all other three groups (p=0.005 for PLPL; p=0.023 for CAPL; and p=0.031 for CFPL). Although the number of gut Bifidobacteria increased in CFCA group, there were no statistically significant differences within and between the groups in any of bacteria numbers. In conclusion, our study showed that 12 weeks consumption of 200 mg/day caffeine plus 200 mg/day chlorogenic acid is effective in reduction of weight in patients with NAFLD and diabetes which might be at least partially through the rise in gut Bifidobacteria. This pilot study shed a light on the pathway of future clinical trials assessing the effects of coffee consumption in these patients. This trial has been registered at clinicaltrial.gov with registration number of NCT02929901.

Keywords: caffeine; chlorogenic acid; clinical trial; coffee; diabetes; fatty liver; microbiota.

Copyright © 2020 Mansour et al.

Figures

Table 1. Primer sequences used for quantitative…
Table 1. Primer sequences used for quantitative real-time PCR assays for each bacteria
Table 2. Baseline characteristics at enrollment 1
Table 2. Baseline characteristics at enrollment1
Table 3. Mean changes (95 % CI)…
Table 3. Mean changes (95 % CI) during study across 4 studied groups
Figure 1. Study consort flow chart
Figure 1. Study consort flow chart
CF, Chlorogenic acid; CA, caffeine; PL, placebo
Figure 2. The log 10 number per…
Figure 2. The log10 number per gram of feces of bacteria in each group
CF, Chlorogenic acid; CA, caffeine; PL, placebo

References

    1. Agudelo-Ochoa GM, Pulgarin-Zapata IC, Velasquez-Rodriguez CM, Duque-Ramírez M, Naranjo-Cano M, Quintero-Ortiz MM, et al. Coffee consumption increases the antioxidant capacity of plasma and has no effect on the lipid profile or vascular function in healthy adults in a randomized controlled trial. J Nutr. 2016;146:524–531.
    1. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(Suppl. 1):S498–S504.
    1. Awaad AS, Soliman GA, Al-Outhman MR, Al-Outhman MR, Zain ME, Moses JE, et al. The effect of four coffee types on normotensive rats and normal/hypertensive human volunteers. Phytother Res. 2011;25:803–808.
    1. Caro-Gomez E, Sierra JA, Escobar JS, Álvarez-Quintero R, Naranjo M, Medina S. Green coffee extract im-proves cardiometabolic parameters and modulates gut microbiota in high-fat-diet-fed ApoE(-/-) mice. Nutrients. 2019;11(3):497.
    1. Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD) Dig Dis Sci. 2010;55:3200–6.
    1. Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol. 2014;29:435–441.
    1. Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38:2552–2557.
    1. Cowan TE, Palmnas MS, Yang J, Bomhof MR, Ardell KL, Reimer RA, et al. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J Nutr Biochem. 2014;25:489–495.
    1. Cuervo A, Hevia A, Lopez P, Suárez A, Diaz C, Sánchez B, et al. Phenolic compounds from red wine and coffee are associated with specific intestinal microorganisms in allergic subjects. Food Funct. 2016;7:104–109.
    1. Gniechwitz D, Reichardt N, Blaut M, Steinhart H, Bunzel M. Dietary fiber from coffee beverage: degradation by human fecal microbiota. J Agri Food Chem. 2007;55:6989–6996.
    1. Gomez-Juaristi M, Martinez-Lopez S, Sarria B, Bravo L, Mateos R. Bioavailability of hydroxycinnamates in an instant green/roasted coffee blend in humans. Identification of novel colonic metabolites. Food Funct. 2018;9:331–343.
    1. Grosso G, Micek A, Godos J, Sciacca S, Pajak A, Martínez-González MA, et al. Coffee consumption and risk of all-cause, cardiovascular, and cancer mortality in smokers and non-smokers: a dose-response meta-analysis. Eur J Epidemiol. 2016;31:1191–1205.
    1. Gutierrez-Grobe Y, Chavez-Tapia N, Sanchez-Valle V, Gavilanes-Espinar JG, Ponciano-Rodríguez G, Uribe M, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of pe-ripheral antioxidant activity. Ann Hepatol. 2012;11:350–355.
    1. Hodge A, Lim S, Goh E, Wong O, Marsh P, Knight V, et al. Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C, and hepatitis B. Nutrients. 2017;9(1):56.
    1. Jaquet M, Rochat I, Moulin J, Cavin C, Bibiloni R. Impact of coffee consumption on the gut microbiota: a human volunteer study. Int J Food Microbiol. 2009;130:117–121.
    1. Jeszka-Skowron M, Zgoła-Grześkowiak A, Grześkowiak T. Analytical methods applied for the characterization and the determination of bioactive compounds in coffee. Eur Food Res Technol. 2015;240:19–31.
    1. Karbaschian Z, Mokhtari Z, Pazouki A, Kabir A, Hedayati M, Moghadam SS, et al. Probiotic supplementation in morbid obese patients undergoing one anastomosis gastric bypass-mini gastric bypass (OAGB-MGB) surgery: a randomized, double-blind, placebo-controlled, clinical trial. Obes Surgery. 2018;28:2874–2885.
    1. Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr. 2010;91:950–957.
    1. Kennedy OJ, Roderick P, Poole R, Parkes J. Coffee, caffeine and non-alcoholic fatty liver disease? Therap Adv Gastroenterol. 2016;9:417–418.
    1. Lecoultre V, Carrel G, Egli L, Binnert C, Boss A, MacMillan EL, et al. Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men. Am J Clin Nutr. 2014;99:268–275.
    1. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assess-ment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
    1. Moisey LL, Kacker S, Bickerton AC, Robinson LE, Graham TE. Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men. Am J Clin Nutr. 2008;87:1254–1261.
    1. Mokhtari Z, Karbaschian Z, Pazouki A, Kabir A, Hedayati M, Mirmiran P, et al. The effects of probiotic supplements on blood markers of endotoxin and lipid peroxidation in patients undergoing gastric bypass surgery; a randomized, double-blind, placebo-controlled, clinical trial with 13 months follow-up. Obes Surg. 2019;29:1248–1258.
    1. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429–436.
    1. Pan MH, Tung YC, Yang G, Li S, Ho CT. Molecular mechanisms of the anti-obesity effect of bioactive compounds in tea and coffee. Food Funct. 2016;7:4481–4491.
    1. Papakonstantinou E, Kechribari I, Sotirakoglou K, Tarantilis P, Gourdomichali T, Michas G, et al. Acute effects of coffee consumption on self-reported gastrointestinal symptoms, blood pressure and stress indices in healthy individuals. Nutr J. 2016;15:26.
    1. Perez-Burillo S, Pastoriza S, Fernandez-Arteaga A, Luzón G, Jiménez-Hernández N, D'Auria G, et al. Spent coffee grounds extract, rich in mannooligo-saccharides, promotes a healthier gut microbial community in a dose-dependent manner. J Agric Food Chem. 2019;67:2500–2509.
    1. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ (Clin Res ed.) 2017;359:j5024.
    1. Rashvand S, Behrooz M, Samsamikor M, Jacobson K, Hekmatdoost A. Dietary patterns and risk of ulcerative colitis: a case-control study. J Hum Nutr Diet. 2018;31:408–412.
    1. Salomone F, Galvano F, Li Volti G. Molecular bases underlying the hepatoprotective effects of coffee. Nutrients. 2017;9(1):85.
    1. Santos RM, Lima DR. Coffee consumption, obesity and type 2 diabetes: a mini-review. Eur J Nutr. 2016;55:1345–1358.
    1. Shaneshin M, Rezazadeh A, Jessri M, Neyestani T, Rashidkhani B. Validity of predictive equations for resting energy expenditure among Iranian women. Asia Pac J Clin Nutr. 2011;20:646–653.
    1. Vaughan MJ, Mitchell T, McSpadden Gardener BB. What's inside that seed we brew? A new approach to mining the coffee microbiome. Appl Environ Microbiol. 2015;81:6518–6527.
    1. Vitaglione P, Fogliano V, Pellegrini N. Coffee, colon function and colorectal cancer. Food Funct. 2012;3:916–922.
    1. Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM. Effects of caffeinated and decaf-feinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J. 2011;10:93.
    1. WHO, World Health Organization. STEPwise approach to surveillance (STEPS) Geneva: WHO; 2012.
    1. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52–59.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅